Literature DB >> 6442282

Capsular polysaccharide vaccines today.

P H Mäkelä.   

Abstract

Polysaccharide (PS) vaccines are a relatively new class of antibacterial vaccines that have special advantages but also special problems related to their character. Several of them have proven very effective in preventing bacteremic infections caused by encapsulated bacteria such as meningococci, pneumococci and Haemophilus influenzae type b. Protective activity shows excellent correlation with serum anti-PS. However, young children often respond poorly to PS antigens and this limits the use of these vaccines in childhood. Some PS are poor immunizing agents even in adults. The practical implications of these aspects for the use and development of PS vaccines are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442282     DOI: 10.1007/bf01641750

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  24 in total

1.  Pneumococcal antigenic polysaccharide substances from animal tissues.

Authors:  L D FELTON; B PRESCOTT; G KAUFFMANN; B OTTINGER
Journal:  J Immunol       Date:  1955-03       Impact factor: 5.422

2.  Long-term sequelae of Hemophilus influenzae meningitis.

Authors:  S H Sell; R E Merrill; E O Doyne; E P Zimsky
Journal:  Pediatrics       Date:  1972-02       Impact factor: 7.124

3.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

4.  Persistence of Pneumococcal antibodies in human subjects following vaccination.

Authors:  P P Vella; A A McLean; A F Woodhour; R E Weibel; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1980-09

5.  IgM and IgG response to pneumococcal polysaccharide vaccine in normal individuals and individuals splenectomized due to trauma.

Authors:  I S Aaberge; H E Heier; E Hem; K E Giercksky; E C Groeng
Journal:  Acta Pathol Microbiol Immunol Scand C       Date:  1984-02

6.  Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.

Authors:  H Peltola; H Mäkelä; H Käyhty; H Jousimies; E Herva; K Hällström; A Sivonen; O V Renkonen; O Pettay; V Karanko; P Ahvonen; S Sarna
Journal:  N Engl J Med       Date:  1977-09-29       Impact factor: 91.245

7.  Adverse reactions and endotoxin content of polysaccharide vaccines.

Authors:  T Kuronen; H Peltola; T Nors; N Haque; P H Mäkelä
Journal:  Dev Biol Stand       Date:  1977

8.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

9.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

10.  PREVENTION OF PNEUMOCOCCAL PNEUMONIA BY IMMUNIZATION WITH SPECIFIC CAPSULAR POLYSACCHARIDES.

Authors:  C M Macleod; R G Hodges; M Heidelberger; W G Bernhard
Journal:  J Exp Med       Date:  1945-11-30       Impact factor: 14.307

View more
  3 in total

1.  Nonionic block polymer surfactants enhance immunogenicity of pneumococcal hexasaccharide-protein vaccines.

Authors:  G J Zigterman; H Snippe; M Jansze; E B Ernste; M J De Reuver; J M Willers
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

2.  Applications of polysaccharides. Patents and literature.

Authors:  R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1986-04       Impact factor: 2.926

3.  Phase-variable bacteria simultaneously express multiple capsules.

Authors:  Samantha A Hsieh; David L Donermeyer; Stephen C Horvath; Paul M Allen
Journal:  Microbiology (Reading)       Date:  2021-07       Impact factor: 2.777

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.